NCT06269211View on ClinicalTrials.gov

Neoadjuvant Toripalimab for Clinically Stage II-IIIB Resectable Non-small Cell Lung Cancer with EGFR Mutation and PD-L1 Positive Expression

PHASE2RecruitingINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

April 20, 2024

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2030

Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
DRUG

Toripalimab

240mg IV, Q3W

Trial Locations (2)

200025

RECRUITING

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai

510180

RECRUITING

Guangdong Provincial People's Hospital, Guangzhou

All Listed Sponsors
collaborator

Guangdong Provincial People's Hospital

OTHER

lead

Ruijin Hospital

OTHER